Browsing category:

Patent Expiration 2013

In June of 1981 the first known cases of AIDS in the United States were reported. Currently there are over 1.7 million people in the United States infected with HIV-1, the virus which causes AIDS, and over more then 600,000 Americans have already died from this ultimately fatal disease. With 1.2 million Americans estimated to[…]

Read More

Duloxetine Hydrochloride CAS# 136434-34-9, is also known as the brand name Cymbalta marketed by Lilly. This effective antidepressant will be going off patent in June of 2013. Duloxetine hydrochloride is currently approved to treat the following: clinical depression; peripheral diabetic neuropathy pain, or nerve pain in the hands, feet, arms, and legs from diabetes; generalized[…]

Read More

As an immunosuppressant drug used to prevent transplant rejection, Sirolimus, CAS number 53123-88-9, is a macrolide. Particularly useful for kidney transplant patients, sirolimus is also known as the brand name Rapamune, which is marketed by Pfizer. The first patent for Rapamune is set to expire in October 2012. An addtional patent will expire in July[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service